Every 8-K that OraSure Technologies Inc (OSUR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow OSUR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OSUR filings page.
OraSure Technologies reported second quarter 2026 net revenues of $30.6 million, up 10% sequentially but down 2% from a year earlier, with core revenues also at $30.6 million and roughly flat year over year. Diagnostics revenue rose 1% to $19.4 million, while Sample Management Solutions revenue was steady at $9.9 million.
GAAP gross margin improved to 43.5% from 42.1%. A $22.6 million reduction of acquisition-related contingent consideration drove GAAP operating income of $5.4 million and GAAP net income of $6.2 million, or $0.09 per diluted share, although non-GAAP results showed a net loss of $13.8 million and non-GAAP diluted loss per share of $0.20.
Cash and cash equivalents totaled $161 million as of June 30 2026. The company has repurchased about $22 million, or 7.7 million shares, of common stock under a $40 million authorization, exceeding 10% of shares outstanding. Recent milestones include FDA clearance of the Colli-Pee™•Dx urine collection kit, FDA Emergency Use Authorization for the OraQuick™ Ebola 2.0 Rapid Antigen Test, and Q3 2026 revenue guidance of $29.5–$32.5 million.
OraSure Technologies, Inc. reported that the U.S. Food and Drug Administration granted clearance for its Colli-Pee™•Dx Urine Collection Kit, developed by subsidiary DNA Genotek Inc., for use with several Roche Molecular Systems tests for common sexually transmitted infections.
The kit is cleared for use with Roche tests for Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium on Roche’s cobas® 5800, 6800, and 8800 molecular diagnostic systems. The FDA-cleared kit supports at-home self-collection of first-void urine, enabling more convenient sample collection for both male and female patients.
OraSure Technologies, Inc. held its 2026 annual stockholder meeting, where stockholders approved an amendment and restatement of the 2000 Stock Award Plan to add authorization for 5,000,000 additional shares of common stock for awards. Stockholders also approved an amendment to the Certificate of Incorporation to declassify the board of directors over three years beginning with the fiscal 2027 annual meeting, so directors standing for election then and thereafter will serve one-year terms.
All three Class II director nominees were elected, Grant Thornton LLP was ratified as independent auditor for 2026, and the advisory vote on executive compensation passed. As of the April 10, 2026 record date, there were 71,965,612 shares of common stock outstanding.
OraSure Technologies reported first quarter 2026 net revenues of $27.9 million, down 7% from $29.9 million a year earlier, as COVID-19 and risk assessment testing revenue largely disappeared while core revenue declined slightly. GAAP gross margin improved to 42.3% from 41.1%, and non-GAAP gross margin rose to 43.4% from 41.7%, reflecting better mix and cost control.
The company posted a GAAP operating loss of $23.3 million and a GAAP net loss of $22.4 million, compared with losses of $17.8 million and $16.0 million in the prior-year quarter. Diluted GAAP loss per share was $0.32, with non-GAAP diluted loss per share of $0.24. Cash and cash equivalents were $177.0 million as of March 31, 2026 after using $5 million to repurchase about 1.8 million shares. For the second quarter of 2026, OraSure guides total revenues to $27–$30 million and expects non-GAAP gross margin similar to the first quarter.
OraSure Technologies entered into a Cooperation Agreement with Altai Capital, under which Altai withdraws its prior director nominations and stockholder proposal and agrees to certain voting and standstill terms through March 31, 2027. The Board appointed John D. Bertrand as an independent Class II director and to the Nominating and Corporate Governance Committee, with his term expiring at the 2026 annual meeting. OraSure will seek stockholder approval at the 2026 annual meeting to declassify the Board, phasing in annual elections for all directors. The company agreed not to increase Board size above eight directors before the 2027 annual meeting without Altai’s consent. Bertrand will receive an initial time-vested equity award of common stock valued at $100,000, vesting two years after grant.
OraSure Technologies furnished an investor presentation addressing its business performance, governance and engagement with Altai Capital ahead of the 2026 annual meeting. The company highlights a focused diagnostics strategy, expecting revenue growth, margin expansion and operating cash flow breakeven in the first half of 2026.
Management points to stabilizing public health funding, planned launches of the Colli-Pee urine collection device and Sherlock CT/NG self-test, and a strong balance sheet with $199 million cash and no debt. A $40 million share repurchase program began in 2025, with $15 million already deployed at an average price of $2.85. The presentation also shows 2025 non‑GAAP gross margin of 42.6% on revenue of $115,021, compared with 39.9% on $387,479 in 2022, and discusses non‑GAAP measures and extensive forward‑looking risks.
OraSure Technologies, Inc. reported a change on its board of directors. On February 28, 2026, director David J. Shulkin, M.D. informed the board that he will resign as a director, including his role on the Compensation Committee, effective March 2, 2026.
The company stated that Dr. Shulkin’s decision to step down is not due to any dispute or disagreement with the board, the company, or its management. The board expressed its appreciation for his years of service and contributions. The filing was signed by President and Chief Executive Officer Carrie Eglinton Manner.
OraSure Technologies reported sharply lower results for the quarter and year ended December 31, 2025 as COVID-related demand faded and core markets softened. Q4 2025 net revenues were $26.8 million, down 29% from $37.4 million a year earlier, and full-year revenues fell to $115.0 million from $185.8 million. The company posted a Q4 GAAP net loss of $19.3 million and a full-year loss of $68.7 million, with Q4 non-GAAP operating loss widening to $15.2 million. Despite the downturn, Q4 non-GAAP gross margin improved to 41.4% and cash and cash equivalents totaled $199 million with no debt.
Core revenues of $26.7 million in Q4 declined 22% year-over-year, driven by a 20% drop in diagnostics sales to $15.1 million and a 39% decline in Sample Management Solutions revenues to $9.1 million. COVID-19 revenues nearly disappeared, falling 95% in Q4 and 99% for the year. Management highlighted cost actions, site consolidations, product line closures, and a $40 million share repurchase program, of which $5 million was used in Q4 to buy back about 1.9 million shares. Looking ahead, the company is guiding Q1 2026 total revenues to $26–29 million and expects low‑40% non-GAAP gross margins, while banking on potential FDA clearances for a rapid molecular self‑test for chlamydia and gonorrhea and the Colli‑Pee urine collection device to help return the business to growth.
OraSure Technologies (OSUR) reported that it issued a press release announcing its consolidated financial results for the quarter ended September 30, 2025. The company also furnished that release as Exhibit 99.1.
Management hosted a webcast with analysts and investors on November 5, 2025 to discuss results and business developments, and furnished an investor presentation as Exhibit 99.2. The materials were provided under Items 2.02 and 7.01 and are described as furnished, not filed.
OraSure Technologies (OSUR) announced Board changes. On October 28, 2025, Mara G. Aspinall resigned as director and chair of the Board, effective immediately, and the company stated her resignation was not due to any dispute or disagreement. The Board appointed John P. Kenny, a current director, as the new chair.
The Board also appointed Steven Boyd as a Class II director effective October 28, 2025, with a term through the 2026 Annual Meeting. He was deemed independent under Nasdaq rules and Rule 10A-3 and will serve on the Audit and Nominating & Corporate Governance Committees. Under the director compensation policy, he will receive time-vested restricted shares valued at $100,000 that vest in two years.